文献速递肝胆胰外科

切除后胰腺导管腺癌驱动基因突变状态与病理特征及总生存的关联

The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Survival.
PubMed 文献 · Ann Surg · 2025-06-18

该研究分析了2018至2022年间接受胰腺切除术的508例局限性胰腺导管腺癌(PDAC)患者,采用靶向下一代DNA测序检测驱动基因突变。结果显示KRAS突变最常见(89.8%),KRAS野生型与较低T分期、N分期及神经侵犯率相关,KRAS和TP53突变与更短中位总生存(mOS)相关,且2个及以上驱动基因突变者mOS更差。

要点

  • KRAS野生型与较低T分期、N分期及神经侵犯率相关。
  • KRAS和TP53突变与更短mOS独立相关。
  • 2个及以上驱动基因突变者mOS较单突变者更差。

核心结论

  • 在切除的PDAC患者中,KRAS野生型和TP53野生型与更好的病理特征及mOS相关, regardless of neoadjuvant therapy。
  • 2个或以上驱动基因突变共存与更差mOS相关。

研究设计与样本

  • 回顾性分析2018至2022年间接受胰腺切除术的局限性PDAC患者508例,均接受靶向下一代DNA测序。

主要发现

  • KRAS突变456例(89.8%),TP53突变292例(57.5%),SMAD4突变104例(20.3%),CDKN2A突变88例(17.3%)。
  • 调整新辅助治疗后,KRAS野生型与较低T分期(P<0.001)、N分期(P=0.04)及较低神经侵犯率(P=0.03)相关。
  • TP53突变较野生型与更高T分期(P=0.02)、神经侵犯(P=0.01)及更高级别肿瘤(P=0.03)相关。
  • KRAS突变与更短mOS相关(HR=2.29,P=0.002),TP53突变与更短mOS相关(HR=1.62,P<0.001)。
  • 多因素分析中,N0分期、解剖可切除及无淋巴血管侵犯与改善mOS相关(所有P<0.02)。

临床怎么用

  • 对切除PDAC患者可考虑驱动基因测序以辅助预后分层。
  • KRAS野生型及TP53野生型提示较好病理特征及生存。
  • 多驱动基因突变共存提示预后更差,需加强随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate whether mutations in pancreatic ductal adenocarcinoma (PDAC) driver genes ( KRAS , TP53 , SMAD4 , and CDKN2A ) are associated with pathological characteristics and prognosis. BACKGROUND: The prognostic significance of specific mutations in PDAC driver genes is incompletely understood. METHODS: We analyzed patients who underwent pancreatectomy between 2018 and 2022 for localized PDAC and whose cancer was profiled using targeted next-generation DNA sequencing. We investigated associations between mutational status, clinical-pathological characteristics, and overall survival (OS). RESULTS: Analysis of 508 patients defined KRAS mutations as the most common genetic mutation (456, 89.8%), followed by TP53 (292, 57.5%), SMAD4 (104, 20.3%), and CDKN2A (88, 17.3%). The presence of wild-type KRAS ( KRAS -wt) was associated with lower T-stage ( P <0.001) and N-stage ( P =0.04) and lower rates of perineural invasion ( P =0.03), when adjusting for receipt of neoadjuvant therapy. TP53 mutations compared with TP53 -wt were associated with higher T-stage ( P =0.02), perineural invasion ( P =0.01), and advanced tumor grade ( P =0.03). Mutations in KRAS and TP53 were associated with shorter mOS compared with wild-type [hazard ratio (HR): 2.29, P =0.002 and HR: 1.62, P <0.001, respectively]. On multivariable analysis, N0 stage, anatomically resectable cancer, and absent lympho-vascular invasion were associated with improved mOS (all P <0.02). The presence of 2 (HR: 1.71) or 3-plus (HR: 1.63) driver mutation genes was associated with shorter mOS compared with one mutation ( P <0.01). CONCLUSIONS: In patients with resected PDAC, KRAS -wt, and TP53 -wt were associated with improved pathological characteristics and mOS, regardless of neoadjuvant therapy. The co-occurrence of 2 or more driver gene mutations was associated with worse mOS.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Campbell BA, Solinas D, Blackford AL, et al. The Mutational Status of Driver Genes in Patients With Resected Pancreatic Ductal Adenocarcinoma Is Associated With Pathological Characteristics and Overall Survival. Ann Surg. 2025. PMID: 40528743. doi:10.1097/SLA.0000000000006794

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。